Baird lowered the firm’s price target on Regeneron (REGN) to $587 from $652 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results while noting Eylea missed already bad expectations.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $700 from $750 at Wells Fargo
- Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
- Regeneron Buy Rating: Navigating Challenges with a Promising Pipeline and Strategic Investments
- Regeneron’s Eylea Challenges Prompt Underperform Rating Amid Market Erosion and FDA Setback
- Regeneron Reports Strong Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue